Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).

Trial Profile

Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tolterodine/pilocarpine (Primary) ; Tolterodine
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2013 Status changed from recruiting to completed according to a TheraVida media release.
    • 02 Apr 2013 Results published in a TheraVida Media Release.
    • 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top